Cameron Turtle

Cameron Turtle

Chief Executive OfficeratSpyre Therapeutics· In proxies 2023–2025

Pay in FY2025-4% from the year before · Spyre Therapeutics stock +40.7% the same year

Cameron Turtle was paid $6.7M in FY2025 (Dec), down 4%. Spyre Therapeutics stock rose 40.7% that year.

Pay$100 in the stock at the end of FY22 → $291
Pay is from the Summary Compensation Table of each Spyre Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Spyre TherapeuticsPublic company · 3 yr
    • Chief Executive Officer2023 – Present · 3 yrStock in role +928%
  2. Oruka TherapeuticsPublic company · 2 yr
    • Director2024 – Present · 2 yrNo stock prices for these years
  3. Damora Therapeutics, Inc.Public company · Less than 1 yr
    • Director2026 – Present · Less than 1 yrNo stock prices for these years
  4. Oruka Therapeutics, Inc.Public company · 1 yr
    • Director2024 – 2025 · 1 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?